var data={"title":"Candida endocarditis and suppurative thrombophlebitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Candida endocarditis and suppurative thrombophlebitis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/contributors\" class=\"contributor contributor_credentials\">Kieren A Marr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> endocarditis is one of the most serious manifestations of candidiasis, and <em>Candida</em> is the most common cause of fungal endocarditis, causing over half of all cases. In a 2001 review of 270 cases of fungal endocarditis in the world literature, the following distribution of organisms was noted [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Candida albicans</em> &ndash; 24 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-albicans species of <em>Candida</em> &ndash; 28 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Aspergillus</em> species &ndash; 24 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Histoplasma capsulatum</em> &ndash; 6 percent</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other &ndash; 17 percent</p><p/><p><em>Candida </em>suppurative thrombophlebitis is an uncommon manifestation of <em>Candida</em> infection.</p><p><em>Candida</em> endocarditis and suppurative thrombophlebitis will be reviewed here. An overview of <em>Candida</em> infections, <em>Candida</em> pericarditis, <em>Aspergillus</em> endocarditis, and fungal cardiac implantable device infections are discussed separately. (See <a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">&quot;Overview of Candida infections&quot;</a> and <a href=\"topic.htm?path=candida-infections-of-the-abdomen-and-thorax#H10\" class=\"medical medical_review\">&quot;Candida infections of the abdomen and thorax&quot;, section on 'Pericarditis'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis#H26\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;, section on 'Role of surgery'</a> and <a href=\"topic.htm?path=infections-involving-cardiac-implantable-electronic-devices\" class=\"medical medical_review\">&quot;Infections involving cardiac implantable electronic devices&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1422983098\"><span class=\"h1\">ENDOCARDITIS</span></p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> endocarditis results from candidemia.</p><p>Risk factors include [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1-12\" class=\"abstract_t\">1-12</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prosthetic heart valves or other valvular disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Injection drug use</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indwelling central venous catheters</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cancer chemotherapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior bacterial endocarditis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low birthweight in neonates</p><p/><p>In the International Collaboration on Endocarditis (ICE) Prospective Cohort Study, 46 percent of 70 cases of <em>Candida</em> endocarditis between 2000 and 2010 were in patients with prosthetic heart valves [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12\" class=\"abstract_t\">12</a>]. Prosthetic valve infection can occur at the time of surgery or later during an episode of candidemia [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/4,6,13\" class=\"abstract_t\">4,6,13</a>]. Contamination of an aortic valve allograft has been reported as the source for <em>Candida</em> prosthetic valve endocarditis [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/14\" class=\"abstract_t\">14</a>].</p><p>The magnitude of risk of endocarditis in patients with candidemia who have prosthetic heart valves was illustrated in a review of 44 patients on a cardiothoracic surgery service who developed nosocomial candidemia [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/15\" class=\"abstract_t\">15</a>]. Seven patients were diagnosed with prosthetic valve endocarditis at the time of candidemia; among the remaining 37 patients, four (11 percent) developed endocarditis at a mean of 232 days (range 26 to 390 days) after candidemia. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of candidemia in adults&quot;</a>.)</p><p>Of the 70 cases in the ICE study described above, the most common species detected were <em>C. albicans</em> (44 percent), <em>C. parapsilosis</em> (27 percent), <em>C. tropicalis</em> (10 percent), and <em>C. glabrata</em> (6 percent) [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12\" class=\"abstract_t\">12</a>]. Injection drug users also most commonly have endocarditis due to <em>C. albicans</em> or <em>C. parapsilosis</em>, but those who use Iranian brown heroin and develop endocarditis almost always have <em>C. albicans</em> because the organism grows abundantly in the lemon juice that is used to cut the heroin [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/7,9\" class=\"abstract_t\">7,9</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations of <em>Candida</em> endocarditis include symptoms and signs of cardiac involvement (dyspnea, edema, or other findings suggestive of congestive heart failure; chest pain; new or changing murmurs on physical examination); embolic phenomena, often involving major vessels supplying the brain, extremities, and the gastrointestinal tract; and systemic symptoms of fever, night sweats, malaise, and weight loss. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of adults with suspected native valve endocarditis&quot;</a>.)</p><p>Arterial embolization is more common in fungal endocarditis than in bacterial endocarditis [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/16,17\" class=\"abstract_t\">16,17</a>], likely a reflection of the larger size of the vegetations associated with fungal endocarditis. The most common sites are the cerebral circulation, extremities, and gastrointestinal tract. Classic signs of endocarditis, such as Osler nodes, Roth spots, and Janeway lesions are infrequently noted [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Patients with <em>Candida</em> endocarditis can develop other complications of candidemia, including endophthalmitis, vertebral osteomyelitis, and meningitis. Thus, all patients should be questioned about and examined for signs of other complications of candidemia. (See <a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">&quot;Treatment of endogenous endophthalmitis due to Candida species&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults&quot;</a>.)</p><p>The diagnosis of <em>Candida</em> endocarditis is often delayed. In one review, fungal endocarditis was characterized by a long duration of symptoms before hospitalization (mean 32 days), extracardiac manifestations, and delayed or missed diagnosis [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1\" class=\"abstract_t\">1</a>]. With increasing use of cardiac echocardiography in the 20 years subsequent to that review, it is likely that the diagnosis is now made more quickly.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic criteria for <em>Candida</em> endocarditis are similar to those for bacterial endocarditis. Blood cultures usually show persistent candidemia, and echocardiography frequently reveals valvular vegetations that are often large. Although transthoracic echocardiography can show vegetations, transesophageal echocardiography is more sensitive and especially useful in patients with prosthetic valve <em>Candida</em> endocarditis [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/6\" class=\"abstract_t\">6</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">&quot;Clinical manifestations and evaluation of adults with suspected native valve endocarditis&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis&quot;</a>.)</p><p>Examination of vegetations or an embolus by histopathology shows yeast forms and by culture yields <em>Candida</em> species.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following section addresses the management of <em>Candida</em> endocarditis of native and prosthetic valves. <em>Candida</em> infection of cardiac implantable devices is discussed separately. (See <a href=\"topic.htm?path=infections-involving-cardiac-implantable-electronic-devices\" class=\"medical medical_review\">&quot;Infections involving cardiac implantable electronic devices&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Combined medical and surgical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon case reports, case series, and clinical experience [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1,6,12,18-31\" class=\"abstract_t\">1,6,12,18-31</a>], a combined approach that utilizes both antifungal agents and valve replacement is recommended for treatment of native and prosthetic valve <em>Candida </em>endocarditis in the 2016 Infectious Diseases Society of America (IDSA) candidiasis guidelines and the 2015 American Heart Association infective endocarditis guidelines [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11,13\" class=\"abstract_t\">11,13</a>]. We agree with this approach.</p><p>There are conflicting data about the mortality rate associated with a combined medical and surgical approach compared with antifungal therapy alone. In a review of cases of fungal endocarditis that occurred between 1965 and 1995, the mortality rate of <em>Candida</em> endocarditis was 59 percent among those who received antifungal therapy alone and 42 percent among those who received combined surgical and antifungal therapy [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1\" class=\"abstract_t\">1</a>]. A subsequent meta-analysis of 72 of 163 patients who had <em>Candida</em> endocarditis between 1980 and 2002 also revealed that better outcomes were associated with a combined surgical and medical therapy approach, but the difference was not statistically significant (odds ratio 0.56, 95% CI 0.16-1.99) [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/31\" class=\"abstract_t\">31</a>]. A subsequent series of 70 cases between 2000 and 2010 found that the mortality rate was similar in patients who received combined medical-surgical therapy and those who received antifungal therapy alone (in hospital mortality: 38 versus 34 percent; 1 year mortality: 66 versus 62 percent) [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Surgical management of endocarditis is discussed in greater detail separately. (See <a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">&quot;Surgery for left-sided native valve infective endocarditis&quot;</a> and <a href=\"topic.htm?path=surgery-for-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Surgery for prosthetic valve endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Initial antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For initial therapy of native or prosthetic valve endocarditis, we recommend <strong>either</strong> (<a href=\"image.htm?imageKey=ID%2F87681\" class=\"graphic graphic_table graphicRef87681 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily) with or without <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> (25 <span class=\"nowrap\">mg/kg</span> orally four times daily in patients with normal renal function)</p><p/><p class=\"bulletIndent1\"><strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An echinocandin at a high dose (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> 150 mg IV daily, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> 150 mg IV daily, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> 200 mg IV daily)</p><p/><p>The therapeutic regimen used most frequently is amphotericin B, with or without <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>. Even though almost all of the reported experience is with <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a>, most patients are now treated with a lipid formulation of amphotericin B in order to reduce nephrotoxicity, and lipid formulations are preferred in the IDSA <em>Candida</em> guidelines. Amphotericin B deoxycholate (1 <span class=\"nowrap\">mg/kg</span> IV daily) can be used as an alternative to a lipid formulation of amphotericin B if a lipid formulation is not available.</p><p><a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">Flucytosine</a> can be added to a lipid formulation of amphotericin B for synergistic activity, but caution must be used to avoid dose-related bone marrow toxicity. Serum flucytosine levels should be monitored routinely, especially if amphotericin B&ndash;associated nephrotoxicity occurs, to keep peak serum drug levels &lt;75 <span class=\"nowrap\">mcg/mL</span>. If flucytosine levels cannot be obtained in a timely fashion and if the patient has renal failure, then the risks of using this agent may outweigh the benefits. (See <a href=\"topic.htm?path=pharmacology-of-flucytosine-5-fc\" class=\"medical medical_review\">&quot;Pharmacology of flucytosine (5-FC)&quot;</a>.)</p><p>There are case reports and small case series of successful treatment of <em>Candida </em>endocarditis with an echinocandin (eg, <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>), either alone or combined with amphotericin B, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12,28,29,32-40\" class=\"abstract_t\">12,28,29,32-40</a>]. The efficacy of the echinocandins for <em>Candida</em> endocarditis has not been proven in clinical trials, but it seems reasonable that these agents, which are fungicidal against many species of <em>Candida</em> and have been proven efficacious for candidemia, could be used for endocarditis. Echinocandins are unique among the systemic antifungal agents in their activity against biofilm-embedded <em>Candida</em> species.(See <a href=\"topic.htm?path=pharmacology-of-echinocandins#H1239292445\" class=\"medical medical_review\">&quot;Pharmacology of echinocandins&quot;, section on 'Candida biofilms'</a>.)</p><p>The most appropriate dosing of the echinocandins for <em>Candida</em> endocarditis has not been studied, but higher doses than normally used for candidemia are recommended and appear to be safe [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11,33,34\" class=\"abstract_t\">11,33,34</a>]. Failure with development of resistance to <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> and other antifungal agents has also been documented [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/41\" class=\"abstract_t\">41</a>].</p><p>Resection of the valve and any associated abscesses is essential for cure in most, but not all, patients. Following surgery, antifungal therapy should be continued for at least six weeks. After the patient's condition has stabilized and the blood cultures have remained negative, therapy can be changed to oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> daily) if the organism is susceptible to complete the course of therapy [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]. Alternative azoles for patients with a <em>Candida</em> isolate that is resistant to fluconazole are discussed below (see <a href=\"#H8\" class=\"local\">'Chronic suppressive therapy'</a> below). Because of the high rates of relapse, many clinicians will treat for longer than six weeks. A total course longer than six weeks is particularly important in patients with perivalvular abscesses and other complications [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>].</p><p>For patients who cannot undergo surgical resection of the affected valve, initial treatment with <strong>either</strong> a lipid formulation of amphotericin B with or without <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> <strong>or</strong> monotherapy with a high dose of an echinocandin followed by lifelong suppression with an oral azole (<a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> if the isolate is susceptible) is recommended in the 2016 IDSA guidelines [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]. Specific recommendations for chronic suppressive therapy are provided below. (See <a href=\"#H8\" class=\"local\">'Chronic suppressive therapy'</a> below.)</p><p><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> should <strong>not</strong> be used as monotherapy for initial therapy of <em>Candida</em> endocarditis [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/23,30\" class=\"abstract_t\">23,30</a>]. In a review of 64 reported cases of <em>Candida</em> endocarditis that were treated with fluconazole alone or combined with another antifungal agent but without surgical intervention, 4 relapses and 11 failures (23 percent) occurred [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/30\" class=\"abstract_t\">30</a>]. Failures were higher in the 19 patients who received only fluconazole (42 percent) than in the group of 45 patients who received fluconazole plus another antifungal agent, usually an amphotericin B formulation (16 percent).</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Chronic suppressive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As discussed above, all patients who cannot undergo surgical resection of the affected valve and patients with prosthetic valve endocarditis should receive lifelong suppression with oral <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> daily) if the <em>Candida</em> isolate is susceptible [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/4-6,11,37,42,43\" class=\"abstract_t\">4-6,11,37,42,43</a>]. Some clinicians will use long-term suppressive antifungal therapy for months or even lifelong even when surgical resection has been performed because of the high relapse rate, especially in patients with complications of endocarditis, such as perivalvular abscesses.</p><p>In patients with endocarditis caused by a <em>Candida</em> species that is not susceptible to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, oral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (200 or 300 mg [3 to 4 <span class=\"nowrap\">mg/kg]</span> twice daily) or delayed-release <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> (300 mg daily) should be used for chronic suppressive therapy if the organism is susceptible. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1393000561\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'C. glabrata and C. krusei'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Neonates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A unique group in which antifungal therapy alone may be effective is that of neonates who have disseminated candidiasis with cardiac thrombi and vegetations [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/8,10\" class=\"abstract_t\">8,10</a>]. The rate of success reported in a review of 30 neonates was 60 percent among the 20 patients treated with medical therapy alone, compared with 60 percent among the 10 patients treated with combined medical and surgical therapy [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/10\" class=\"abstract_t\">10</a>].</p><p>In neonates with <em>Candida</em> endocarditis, we suggest <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (1 <span class=\"nowrap\">mg/kg</span> IV daily) [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]. <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">Flucytosine</a> may be added, but toxicity is greater in neonates than in adults, and a strong recommendation cannot be made to use this agent for this population [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/44\" class=\"abstract_t\">44</a>]. As with adults, after the patient has stabilized and the blood cultures are negative, the patient can be switched to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> if the <em>Candida</em> isolate is susceptible.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Relapse</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Relapses are common, even with surgical resection and treatment with amphotericin B [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1,2,4,5,42\" class=\"abstract_t\">1,2,4,5,42</a>]. For example, in one small case series, 4 of 10 patients had a late relapse (mean 25 months) despite a combined therapy approach [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/4\" class=\"abstract_t\">4</a>]. Because of the risk of relapse, careful follow-up is essential, even after apparently successful therapy.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In an international multicenter prospective cohort study that included 70 cases of <em>Candida</em> endocarditis between 2000 and 2010, in-hospital mortality was 36 percent and mortality at one year was 59 percent [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H4257225163\"><span class=\"h1\">SUPPURATIVE THROMBOPHLEBITIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Candida</em> suppurative thrombophlebitis is an uncommon manifestation of invasive candidiasis. The approach to therapy includes antifungal therapy as well as removal of the intravenous catheter [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]. In addition, incision and drainage or resection of the vein should be performed, if feasible. However, when a central vein is involved, resection is not usually possible.</p><p>Most experience treating <em>Candida</em> thrombophlebitis has been with amphotericin B, but <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> have been reported to be effective [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11,45-47\" class=\"abstract_t\">11,45-47</a>]. Other agents used for the treatment of candidemia, such as the other echinocandins (<a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>) and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> are also likely to be effective [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/48\" class=\"abstract_t\">48</a>]. As with the treatment approach to <em>Candida</em> endocarditis, higher-than-usual doses of the echinocandins should be used [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H7\" class=\"local\">'Initial antifungal therapy'</a> above.)</p><p>For initial antifungal therapy of <em>Candida</em> thrombophlebitis, we recommend <strong>either</strong> (<a href=\"image.htm?imageKey=ID%2F87681\" class=\"graphic graphic_table graphicRef87681 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily)</p><p/><p class=\"bulletIndent1\"><strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> (400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> IV or orally daily)</p><p/><p class=\"bulletIndent1\"><strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An echinocandin at a high dose (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> 150 mg IV daily, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> 150 mg IV daily, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> 200 mg IV daily)</p><p/><p>One of these regimens should be continued for at least two weeks after candidemia (if present) has cleared. Step-down therapy with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (at the same doses recommended above) can be used in those initially treated with amphotericin B or an echinocandin who have responded to the initial regimen, are clinically stable, and have a fluconazole-susceptible isolate. In patients who have responded clinically and whose cultures have cleared, antifungal therapy can be discontinued once resolution of the thrombus is documented.</p><p>Systemic anticoagulation or thrombolytic therapy has been used as adjunctive therapy in some cases, but there is inadequate evidence to recommend these modalities [<a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H3584861017\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Candidiasis&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-treatment-and-prevention-of-infective-endocarditis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Treatment and prevention of infective endocarditis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Candida</em> endocarditis is one of the most serious manifestations of candidiasis, and <em>Candida</em> is the most common cause of fungal endocarditis. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Candida</em> endocarditis results from candidemia. Risk factors include prosthetic heart valves or other valvular disease, injection drug use, indwelling central venous catheters, cancer chemotherapy, prior bacterial endocarditis, and, in neonates, low birthweight. (See <a href=\"#H2\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical manifestations of <em>Candida</em> endocarditis include symptoms and signs of cardiac involvement (dyspnea, edema, or other findings suggestive of congestive heart failure; chest pain; new or changing murmurs on physical examination); embolic phenomena, often involving major vessels supplying the brain, extremities, and the gastrointestinal tract; and systemic symptoms of fever, night sweats, malaise, and weight loss. (See <a href=\"#H3\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnostic criteria for <em>Candida</em> endocarditis are similar to those for bacterial endocarditis. Blood cultures usually show persistent candidemia, and echocardiography frequently reveals valvular vegetations that are often large. (See <a href=\"#H4\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with native or prosthetic valve <em>Candida</em> endocarditis, we suggest a combined approach that utilizes both antifungal agents and valve replacement rather than antifungal therapy alone (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H6\" class=\"local\">'Combined medical and surgical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For initial antifungal therapy of <em>Candida </em>endocarditis, we recommend <strong>either</strong> a lipid formulation of amphotericin B at a dose of 3 to 5 <span class=\"nowrap\">mg/kg</span> intravenous (IV) daily with or without <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> (25 <span class=\"nowrap\">mg/kg</span> orally four times daily in patients with normal renal function) <strong>or</strong> an echinocandin at a high dose (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> 150 mg IV daily, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> 150 mg IV daily, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> 200 mg IV daily) (<a href=\"image.htm?imageKey=ID%2F87681\" class=\"graphic graphic_table graphicRef87681 \">table 1</a>) (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> (1 <span class=\"nowrap\">mg/kg</span> IV daily) can be used as an alternative to a lipid formulation of amphotericin B if a lipid formulation is not available. (See <a href=\"#H7\" class=\"local\">'Initial antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with <em>Candida</em> endocarditis who are infected with susceptible <em>Candida</em> spp and who are clinically stable and have cleared <em>Candida</em> from the bloodstream following initial antifungal therapy and valve surgery, we suggest stepdown therapy with an oral azole (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If the <em>Candida</em> isolate is susceptible to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, it should be given at a dose of 400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> daily. If the <em>Candida</em> isolate is not susceptible to fluconazole, oral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (200 or 300 mg [3 to 4 <span class=\"nowrap\">mg/kg]</span> twice daily) or delayed-release <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> (300 mg daily) should be used. Treatment should be continued for at least six weeks following surgery. However, due to the high rates of relapse, especially in those who have a complication, such as a perivalvular abscess, many clinicians prefer to extend treatment longer than six weeks and follow clinical and laboratory parameters to decide on the total duration of therapy. (See <a href=\"#H7\" class=\"local\">'Initial antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with <em>Candida</em> endocarditis who cannot undergo surgical resection of the affected valve and patients with prosthetic valve endocarditis, initial antifungal therapy (with either a lipid formulation of amphotericin B with or without <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> or a high dose of an echinocandin) should be followed by lifelong suppression with an oral azole (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If the <em>Candida</em> isolate is susceptible to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>, it should be given at a dose of 400 to 800 mg (6 to 12 <span class=\"nowrap\">mg/kg)</span> daily. If the <em>Candida</em> isolate is not susceptible to fluconazole, oral <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (200 or 300 mg [3 to 4 <span class=\"nowrap\">mg/kg]</span> twice daily) or delayed-release <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> (300 mg daily) should be used. (See <a href=\"#H8\" class=\"local\">'Chronic suppressive therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For neonates with <em>Candida</em> endocarditis in the absence of another indication for surgery, we suggest antifungal therapy without valve replacement (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">Amphotericin B deoxycholate</a> (1 <span class=\"nowrap\">mg/kg</span> IV daily) is the drug of choice in neonates. (See <a href=\"#H9\" class=\"local\">'Neonates'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For initial antifungal therapy of <em>Candida </em>thrombophlebitis, we recommend <strong>either</strong> a lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> IV daily) <strong>or</strong> <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 to 800 mg [6 to 12 <span class=\"nowrap\">mg/kg]</span> IV or orally daily) <strong>or</strong> an echinocandin at a high dose (<a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> 150 mg IV daily, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> 150 mg IV daily, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> 200 mg IV daily) (<a href=\"image.htm?imageKey=ID%2F87681\" class=\"graphic graphic_table graphicRef87681 \">table 1</a>) (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). Recommendations for step-down therapy and duration of therapy are discussed above. We also recommend removal of the IV catheter (<a href=\"grade.htm?i=3\" class=\"grade\">Grade 1C</a>). In addition, incision and drainage or resection of the vein should be performed, if feasible. (See <a href=\"#H4257225163\" class=\"local\">'Suppurative thrombophlebitis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/1\" class=\"nounderline abstract_t\">Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/2\" class=\"nounderline abstract_t\">Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122:302.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/3\" class=\"nounderline abstract_t\">Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/4\" class=\"nounderline abstract_t\">Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995; 60:538.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/5\" class=\"nounderline abstract_t\">Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997; 76:94.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/6\" class=\"nounderline abstract_t\">Nguyen MH, Nguyen ML, Yu VL, et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22:262.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/7\" class=\"nounderline abstract_t\">Mir&oacute; JM, Puig de la Bellacasa J, Odds FC, et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis 1987; 156:857.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/8\" class=\"nounderline abstract_t\">Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/9\" class=\"nounderline abstract_t\">Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/10\" class=\"nounderline abstract_t\">Levy I, Shalit I, Birk E, et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006; 49:43.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/11\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/12\" class=\"nounderline abstract_t\">Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother 2015; 59:2365.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/13\" class=\"nounderline abstract_t\">Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/14\" class=\"nounderline abstract_t\">Kuehnert MJ, Clark E, Lockhart SR, et al. Candida albicans endocarditis associated with a contaminated aortic valve allograft: implications for regulation of allograft processing. Clin Infect Dis 1998; 27:688.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/15\" class=\"nounderline abstract_t\">Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103:25.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/16\" class=\"nounderline abstract_t\">Rubinstein E, Noriega ER, Simberkoff MS, et al. Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) 1975; 54:331.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/17\" class=\"nounderline abstract_t\">Ellis M. Fungal endocarditis. J Infect 1997; 35:99.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/18\" class=\"nounderline abstract_t\">Melamed R, Leibovitz E, Abramson O, et al. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis 2000; 32:86.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/19\" class=\"nounderline abstract_t\">Czwerwiec FS, Bilsker MS, Kamerman ML, Bisno AL. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med 1993; 94:545.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/20\" class=\"nounderline abstract_t\">Lejko-Zupanc T, Kozelj M. A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone. J Infect 1997; 35:81.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/21\" class=\"nounderline abstract_t\">Aaron L, Therby A, Viard JP, et al. Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis. Scand J Infect Dis 2003; 35:351.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/22\" class=\"nounderline abstract_t\">Zahid MA, Klotz SA, Hinthorn DR. Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis. Chest 1994; 105:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/23\" class=\"nounderline abstract_t\">Castiglia M, Smego RA Jr, Sames EL. Candida endocarditis and amphotericin B intolerance: potential role for fluconazole. Infect Dis Clin Pract 1994; 3:248.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/24\" class=\"nounderline abstract_t\">Wells CJ, Leech GJ, Lever AM, Wansbrough-Jones MH. Treatment of native valve Candida endocarditis with fluconazole. J Infect 1995; 31:233.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/25\" class=\"nounderline abstract_t\">Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14:422.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/26\" class=\"nounderline abstract_t\">Mayrer AR, Brown A, Weintraub RA, et al. Successful medical therapy for endocarditis due to Candida parapsilosis. A clinical and epidemiologic study. Chest 1978; 73:546.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/27\" class=\"nounderline abstract_t\">Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole. Scand J Infect Dis 2005; 37:310.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/28\" class=\"nounderline abstract_t\">Jim&eacute;nez-Exp&oacute;sito MJ, Torres G, Barald&eacute;s A, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39:e70.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/29\" class=\"nounderline abstract_t\">Rajendram R, Alp NJ, Mitchell AR, et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005; 40:e72.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/30\" class=\"nounderline abstract_t\">Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore) 2011; 90:237.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/31\" class=\"nounderline abstract_t\">Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005; 51:230.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/32\" class=\"nounderline abstract_t\">Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of new antifungal agents. Mycoses 2009; 52:60.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/33\" class=\"nounderline abstract_t\">Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/34\" class=\"nounderline abstract_t\">De Rosa FG, D'Avolio A, Corcione S, et al. Anidulafungin for Candida glabrata infective endocarditis. Antimicrob Agents Chemother 2012; 56:4552.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/35\" class=\"nounderline abstract_t\">Mr&oacute;wczy&#324;ski W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J 2004; 23:376.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/36\" class=\"nounderline abstract_t\">Bacak V, Biocina B, Starcevic B, et al. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature. J Infect 2006; 53:e11.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/37\" class=\"nounderline abstract_t\">Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005; 24:753.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/38\" class=\"nounderline abstract_t\">L&oacute;pez-Ciudad V, Castro-Orjales MJ, Le&oacute;n C, et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006; 6:73.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/39\" class=\"nounderline abstract_t\">Falcone M, Barzaghi N, Carosi G, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 2009; 88:160.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/40\" class=\"nounderline abstract_t\">Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect 2012; 18:E99.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/41\" class=\"nounderline abstract_t\">Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49:767.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/42\" class=\"nounderline abstract_t\">Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis 1996; 22:348.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/43\" class=\"nounderline abstract_t\">Penk A, Pittrow L. Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. Mycoses 1999; 42 Suppl 2:91.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/44\" class=\"nounderline abstract_t\">Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/45\" class=\"nounderline abstract_t\">Friedland IR. Peripheral thrombophlebitis caused by Candida. Pediatr Infect Dis J 1996; 15:375.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/46\" class=\"nounderline abstract_t\">Benoit D, Decruyenaere J, Vandewoude K, et al. Management of candidal thrombophlebitis of the central veins: case report and review. Clin Infect Dis 1998; 26:393.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/47\" class=\"nounderline abstract_t\">Block AA, Thursky KA, Worth LJ, Slavin MA. Thrombolytic therapy for management of complicated catheter-related Candida albicans thrombophlebitis. Intern Med J 2009; 39:61.</a></li><li><a href=\"https://www.uptodate.com/contents/candida-endocarditis-and-suppurative-thrombophlebitis/abstract/48\" class=\"nounderline abstract_t\">Pan SC, Hsieh SM, Chang SC, et al. Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents. Med Mycol 2005; 43:731.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2423 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1422983098\" id=\"outline-link-H1422983098\">ENDOCARDITIS</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Risk factors</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Clinical features</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Diagnosis</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Treatment</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Combined medical and surgical approach</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Initial antifungal therapy</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Chronic suppressive therapy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Neonates</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">Relapse</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Mortality</a></li></ul></li><li><a href=\"#H4257225163\" id=\"outline-link-H4257225163\">SUPPURATIVE THROMBOPHLEBITIS</a></li><li><a href=\"#H3584861017\" id=\"outline-link-H3584861017\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2423|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/87681\" class=\"graphic graphic_table\">- Treatment of Candida cardiovascular infections</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=candida-infections-of-the-abdomen-and-thorax\" class=\"medical medical_review\">Candida infections of the abdomen and thorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-evaluation-of-adults-with-suspected-native-valve-endocarditis\" class=\"medical medical_review\">Clinical manifestations and evaluation of adults with suspected native valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">Epidemiology and pathogenesis of candidemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infections-involving-cardiac-implantable-electronic-devices\" class=\"medical medical_review\">Infections involving cardiac implantable electronic devices</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-candida-infections\" class=\"medical medical_review\">Overview of Candida infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-echinocandins\" class=\"medical medical_review\">Pharmacology of echinocandins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-flucytosine-5-fc\" class=\"medical medical_review\">Pharmacology of flucytosine (5-FC)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">Society guideline links: Candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-treatment-and-prevention-of-infective-endocarditis\" class=\"medical medical_society_guidelines\">Society guideline links: Treatment and prevention of infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgery-for-left-sided-native-valve-infective-endocarditis\" class=\"medical medical_review\">Surgery for left-sided native valve infective endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgery-for-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Surgery for prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">Treatment and prevention of invasive aspergillosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Treatment of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-endogenous-endophthalmitis-due-to-candida-species\" class=\"medical medical_review\">Treatment of endogenous endophthalmitis due to Candida species</a></li></ul></div></div>","javascript":null}